Tests liver-directed tirapazamine embolization with pembrolizumab for liver-spread cancers
Tests a combined liver treatment with pembrolizumab in adults with colorectal or lung cancer.
Key facts
- Who runs it
- Teclison Ltd.
- Where
- Hsinchu and Taichung, TaiwanSee the 2 sitesAlso in 1 other country, 1 site
- Trial code
- Registry title
- TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 110 people, planned
- Started
- 20 May 2021
- Expected to end
- 30 Sept 2027
- Type of study
- Interventional, 2 groups
- Treatments tested
- TATE and pembrolizumab
- TAS-102 pill
- Regorafenib Pill
- Record updated
- 16 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with colorectal cancer or non-small cell lung cancer that has spread to the liver and has not responded to earlier treatment.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Liver metastatic MSS-mCRC or NSCLC without EGFR or AKT mutations; measurable disease; ECOG 0-1
- Earlier treatment
- Colorectal cancer: progressed on at least two lines of standard chemotherapy. Lung cancer: progressed on chemotherapy and an immune checkpoint inhibitor. At least 4 weeks since last chemotherapy and free from chemo-related toxicity.
- Biomarker or test result
- Lung cancer without EGFR or AKT mutations
Main reasons for not taking part
- Prior organ transplantation
- Liver metastasis more than 50%
- Oxygen saturation less than 92% in room air
- Prior autoimmune disorder
- CNS metastasis
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Liver metastatic MSS-mCRC or NSCLC without EGFR or AKT mutations
- mCRC progressed on at least two lines of standard chemotherapy; or
- NSCLC progressed on chemotherapy and an immune checkpoint inhibitor
- Measurable disease
- ECOG 0-1
- At least 4 weeks from prior chemotherapy and free from chemo-related toxicity
- Adequate organ function
Who cannot take part
- Prior organ transplantation
- Prior autoimmune disorder
- Major GI bleeding in the last 2 months
- Liver metastasis more than 50%
- Oxygen saturation less than 92% in room air
- CNS metastasis
Where in Taiwan
Also in 1 other country, 1 site
- China Medical University Hsinchu HospitalHsinchu, TaiwanContact: sandy LaiTaking people
- Chung Shan Medical University HospitalTaichung, TaiwanContact: Sandy LaiTaking people
About the trial
What the trial wants to find out
Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.
The 2 groups in the trial
- colorectal cancerTreatment being tested
metastatic colorectal cancer progressed on at least two lines of chemotherapy
Treatment: TATE and pembrolizumab, TAS-102 pill, and Regorafenib Pill
- NSCLCTreatment being tested
Liver metastatic NSCLC progressed on immune checkpoint inhibitors and chemotherapy
Treatment: TATE and pembrolizumab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- An Open Label Phase II Study for the Treatment of Liver Metastatic Colorectal Cancer and Non-Small Cell Lung Cancer With a Combination of TATE (Trans-Arterial Tirapazamine Embolization) and Pembrolizumab
- Plain-language title
- Tests liver-directed tirapazamine embolization with pembrolizumab for liver-spread cancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 16 April 2026